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Introduction
The incidence of infertility is increasing day by day
throughout the world. Anti-neoplastic treatment is
emerging as an added cause of secondary infertility
along with numerous other reasons.1 Advancements in
cancer management have undoubtedly improved the
survival rates but efforts to conserve quality of life even
after chemotherapy administration is still under
exploration. As these agents mainly act against
proliferating cancer cells, it is not surprising to observe
their toxic effects on normal growing cells such as bone
marrow, gastric mucosa and ovarian follicles.2
Chemotherapeutic drugs are broadly classified into three
groups based on their ability to cause ovarian toxicity.
Among these, the high-risk group is associated with an
overall 80% chance of premature ovarian failure (POF)
which mostly comprises alkylating agents such as
cyclophosphamide (CYP), busulfan and chlorambucil.3
POF is a leading cause of infertility and increases the risk
for developing cardiovascular diseases, osteoporosis,
Alzheimer's disease and colorectal or ovarian cancer at
an earlier age.4
Nowadays, massive efforts are being made to preserve
fertility in young women exposed to gonadotoxic
chemotherapy. As the chemotherapeutic drugs cause
destruction to ovaries, it leads to defective
folliculogenesis as well as steroidogenesis.5 Various
biochemical and biophysical markers are evaluated to
monitor ovarian reserve (OR) that helps to ascertain
patients' state of ovarian toxicity. Unfortunately,
traditional markers such as follicle stimulating
hormone (FSH), luteinising hormone (LH), estradiol and
inhibin B, all exhibit low sensitivity in the initial stages
of OR damage.6
Recently, anti-mullerian hormone (AMH) has arisen as
the best single marker of OR quantification.7 Numerous
researches have highlighted the clinical implications of
AMH analysis, including potential role in polycystic
ovarian syndrome diagnosis, estimation of age at
menopause and prediction of ovarian response in
assisted reproduction.8 In females, this peptide
hormone is exclusively secreted by the granulosa cells
of early growing ovarian follicles. It influences the
folliculogenesis by regulating initial selection of
follicles, their growth and threshold for FSH
sensitivity.9 Furthermore, as serum AMH deranges
earlier than FSH, efforts are being made to use it as a
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Abstract
Objective: To evaluate the strength of anti-mullerian hormone in reflecting the stages of ovarian toxicity-induced
by cyclophosphamide.
Methods: This study was conducted in December 2014 and comprised female mice that were divided into four
groups: group A served as control, group B received three weekly injections of cyclophosphamide, group C was co
administered alpha-tocopherol along with cyclophosphamide, while group D solely received alpha-tocopherol. The
ovaries were evaluated for follicular dynamics, and anti-mullerian hormone was assessed using mouse enzyme-
linked immunosorbent assay kit. The data was analysed using SPSS 19.
Results: There were 40 mice in the study. Histological analysis revealed severely reduced ovarian reserve in group
B(p<0.01).In group C alpha-tocopherol conserved the ovarian reserve to near normal, thus follicle count was
significantly higher than group B (p<0.05). However, this moderate reduction was still lower than the controls
(p<0.01). Furthermore, the number of corpus lutea and atretic follicles were significantly higher in groups B and C
(p<0.01). Regarding hormonal analyses in comparison to controls, anti-mullerian hormone levels were low in group
B (p<0.01), while group C reported an insignificant fall in serum anti-mullerian hormone levels (p=0.101). 
Conclusion: There was substantial evidence that anti-mullerian hormone monitoring during chemotherapy
administration may fulfil the criteria of earliest diagnostic indicator of secondary infertility. 
Keywords: Anti-mullerian hormone, Chemotherapy, a-tocopherol, Ovarian reserve, Cyclophosphamide.
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diagnostic marker of acute ovarian insufficiency due to
cancer treatment.10
The current study was planned to evaluate the strength
of AMH in reflecting various stages of ovarian
insufficiency. To achieve this goal, we imitated three
levels of ovarian toxicity in mice model. CYP
chemotherapy was administered to conceive severely
reduced OR while alpha (a)-tocopherol was co-
administered to ameliorate its effect, creating moderate
level of ovotoxicity. These findings were compared with
controls that served as a model of normal reserve. Our
results confirm that as opposed to other markers, serum
AMH proportionately reflects the ovarian reserve in
acute ovarian insufficiency.
Materials and Methods
This study was conducted in December 2014 at the
Animal house, Ojha Campus Dow University of Health
Sciences (DUHS). Ethical approval was obtained from
the institutional review board of the Dow University
of Health Sciences. Ten-week-old Naval Medical
Research Institute (NMRI) strain female mice,
weighing between 22g and 28g were included in this
study. They were acclimatised for two weeks under
normal circadian rhythm of 12 hours light and 12
hours dark to assess their state of health. The food
and water was provided ad libitum. Diseased,
pregnant or medically unfit animals were excluded on
the bases of weight gain or loss. 
The animals were divided into four equal groups. Group A
received three weekly intraperitoneal dose of sterile
water and served as controls. Group B received
intraperitoneal CYP injection (Endoxane, Baxter Oncology
GmbH, Frankfurt) at a dose of 75mg/kg body weight
dissolved in sterile water, once a week for 3 weeks.11
Group C received three weekly doses of CYP (75mg/kg
body weight) along with daily oral dose of alpha-
tocopherol (Evion, Merck, Pakistan) 150mg/kg. Group D
received oral dose of alpha-tocopherol (150mg/kg) daily
for three weeks by oral gavage. 
Each animal was weighed at the start and on completion
of the study. The mice were sacrificed under deep
anaesthesia and dissected through midline abdominal
incision, extending from xiphoid process to anterior
pelvic wall. 
Thoracic cage was retracted to collect blood via cardiac
puncture. After centrifugation for 10 minutes at 3,000
revolutions per minute (rpm), the serum samples were
stored at -20ºC. The serum AMH was evaluated by
mouse enzyme-linked immunosorbent assay (ELISA) kit
(USCN Life Science Inc., Cloud-Clone Corporation,
United States). 
The abdominal cavity was exposed and bi-cornuate
uterus was followed to the gonads. Ovaries were
dissected out from surrounding tissues and weighed on
Sartorius make (MC 210 P) balance which had a minimum
scale of 0.0l mg. The external features like colour,
contour, consistency, vascularity and haemorrhagic
necrosis were observed in the ovary of each animal. Only
right ovary was evaluated to maintain uniformity and
prevent any discrepancy as suggested by the literature.11
Afterwards, the ovaries were preserved in Bouin's fluid
for 12 hours followed by immersion in 70% ethanol
saturated with lithium carbonate, to remove excessive
picric acid. After processing, 5µm thick serial sections
were prepared using rotary microtome. Every fifth
section was stained with routine haematoxylin and eosin
and the slides were mounted for further evaluation. 
Around15-20 slides (every fifth section) were prepared for
estimation of follicle count from each ovary. Blind manual
counting was performed by a single observer to avoid
biasness due to prior knowledge.12 Only follicles having
clearly visible nucleus within oocyte were counted to rule
out the chance of recounting an oocyte. The slides were
closely examined at 40x magnification and the number of
various follicles was separately noted for each animal. 
Data was analysed using SPSS 19. Mean ± standard
deviation (SD) were reported for all measured variables.
Comparison of means was made using one-way analysis
of variance (ANOVA). For further investigation, Tukey's
honest significant difference (HSD) test of multiple
comparisons was employed to confirm the pair wise
comparison at 5 % level of significance (95% confidence
interval [CI]). P<0.05 was considered statistically
significant.
Results
There were 40 mice in the study. The effect of CYP was
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Table: Multiple comparison of serum levels of anti-mullerian hormone amongst the
groups.
Conditions                                                         Conditions                                             p-value
Controls                                                                        CYP                                                    <0.001*
                                                                            CYP+ tocopherol                                            0.07
                                                                                  tocopherol                                                   0.93
CYP                                                                    CYP+ tocopherol                                           0.01*
                                                                                  tocopherol                                               0.002*
CYP+ tocopherol                                                 tocopherol                                                  0.74
*p <0.05 considered significant using Tukey post hoc analyses.
CYP: Cyclophosphamide.
observed on the morphology of ovaries of mice and was
correlated with hormonal levels of AMH amongst the four
groups. 
Group A mice gained significant weight (p<0.05), whereas
there was no weight change in group B. Group C reported
an insignificant weight gain (p=0.34) and group D gained
the weight similar to group A. Regarding the absolute
weight of the ovaries, there was an insignificant
difference amongst the four
groups (p=0.072). The mean
weight of ovaries in the control
group A was 9.65±0.88mg, group
B 8.62±0.83mg, group C
9.35±0.97mg, and group D
9.55±0.99mg. 
In comparison to group A, group B
reported the highest decline in
the follicle reserve. The number of
primordial, primary as well as
secondary follicles were found to
be significantly low (p<0.001).
Regarding group C, the mean
number of primordial and primary
follicles showed significant
reduction in comparison to
controls (p<0.01), but the decline
in the number of secondary
follicles was insignificant
(p=0.109). The follicular dynamics
in group D were conserved to near
normal (p=0.90). The mean
number of total follicles in group
A was 183.6±9.24, group B was
77.3±9.67, group C was
141.7±8.93 and group D was
170±12.97.
Furthermore, when compared
with control group A, the largest
number of atretic follicles was
found in group B, followed by
group C (12.5±2.55 and 10±4.11,
respectively). This count was
significantly lower in controls as
well as group D (2.5±1.43 and
2.2±1.08, respectively). Similarly,
corpora lutea was 2.3±0.94 in
group A, 2.0±0.66 in group D,
5.7±1.88 in group B and 4.2±1.68
in group C (Figure-1).
Serum AMH in controls was
29.60±12.24 ng/ml, in group B it was 9.88±8.74 ng/ml, in
group C it was 21.79±10.06 ng/ml and in group D it was
26.92±9.9 ng/ml (Figure-2). 
Post hoc analysis revealed that in group B serum AMH was
significantly lower in comparison to all other groups. The
difference in serum AMH amongst controls and group C
was insignificant (p>0.05). The serum AMH values in
group D were comparable to controls (p=0.93) (Table).
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Figure-1: Graphical comparison between the numbers of follicles in groups.
CYP: Cyclophosphamide
AMH: Anti-mullerian hormone
Figure-2: Effective classification of study animals based on Serum AMH levels (ng/ml). Normal serum AMH values for mice
were obtained from the experiment study of Kevenaar et al.23
Discussion
This study evaluated the role of AMH in accurate
reflection of OR in various stages of acute ovarian
insufficiency. Hence, to create this model of ovotoxicity,
we administrated CYP chemotherapy to mice. 
In rodents, the effects of CYP have been observed at
varied strengths, ranging from 40 to 300 mg/kg, in single
or multiple dosages.13,14 We administered three weekly
doses (75mg/kg) to replicate model of human ovarian
damage caused by multiple doses of chemotherapy. This
non-sterilising dose of CYP created an ideal model to
study the follicular and hormonal dynamics spanning
over five to six estrous cycles. As the literature supported
the protective role of a-tocopherol, we employed it
against CYP-induced ovarian toxicity in group C to imitate
moderate ovarian damage.11 Aiming to exploit the
potential impact of acute ovarian damage on follicular
dynamics and serum AMH production, we were able to
study three levels of OR; normal (group A and D),
moderately decreased (group C) and severely decreased
(group B). 
In our study, gross morphological features of ovaries such
as colour, consistency and
vascularity were found to be
conserved. After treatment,
there was an insignificant
difference in weights of
ovaries amongst the four
groups. A slightly lower
weight and loss of nodularity
of ovaries was noticed in the
CYP-treated group (Figure-3).
In agreement to previous data,
we suggest that acute damage
may not alter size or external
features of gonads.11
Therefore, the absence of
gross changes suggests that
the monitoring of ovarian
volume is not an ideal marker
to scan ovarian injury. 
The crucial step to ascertain
reproductive capability of
ovaries is to ascertain the
number of various follicles
with cortex, especially,
primordial follicles.15 We
manually counted the follicles
to observe their dynamics.
CYP administration affected
entire cohort leading to
drastic fall in group B. The greatest destruction was
noticed on primordial and primary follicles, strongly
predicting premature ovarian failure in the near future.
Consumption of primordial follicles logically predicts a
decline of all other growing follicles. As reported by Saleh
HS, the primary and secondary follicles expresses highest
mitotic index, thus are prone to deoxyribonucleic
acid(DNA) cross-linking induced by anti-tumour drugs.16
Our findings are consistent with the study of Yan Jiang et
al., who reported upto 56% reduction in the number of
primordial and primary follicles in CYP-treated mice.17
Furthermore, we observed a rise in the number of atretic
follicles and corpora lutea in group B. This suggests higher
turnover of follicles that finally ends into atresia. With the
administration of CYP that led to exhaustion of ovarian
pool, we were able to create a model of severely reduced
OR in vivo.
The protective role of a-tocopherol is well established in
different biological systems such as maintenance of cell
structure, ischaemia and reperfusion injuries.18 It is
effective against ovarian toxicity induced by chromium,
carbon monoxide pneumo-peritoneum and
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CYP: Cyclophosphamide
Figure-3: H & E stained photomicrograph at 10x magnification showing ovaries collected from various groups. Control group (A),
CYP treated group (B), CYP + a-tocopherol treated group (C) and a-tocopherol treated group(D). The loss of contour nodularity
and follicular pool in visible in B.
chemotherapies.19 In order to utilise its ameliorating
effect, we co-administered it with CYP in group C. In line
with a previous study conducted by Seren Gulsen, we
endorse that a-tocopherol conserves ovarian
parameters, when co administered with CYP.11 In
common agreement to our results, he reported that
most obvious protective effect was seen on early
follicles. The secondary follicles were conserved to near
normal as well. On the other hand, group C reported
higher count of atretic follicles and corpora lutea in
comparison to controls. This suggests that although a-
tocopherol prevented follicles from CYP-induced
destruction, there was high turnover of follicles from
dormant to growing stage. Group C served as a useful
model of moderate ovarian damage with a greater OR in
comparison with group B. The protective role of a-
tocopherol might be explained by the fact that it
balanced excessively produced reactive oxygen species
(ROS) under influence of CYP, conserving the cell
architecture against free radical injury. While
maintaining the balance, it has shown promising results
in preserving the number of primordial, primary and
secondary follicles; however, it has not been able to
reduce the number of atretic follicles within CYP
exposed ovaries.   
As ovaries secrete a number of biomarkers, ideally its
destruction is reflected by deranged hormonal levels.
Regrettably, literature suggests normal levels of FSH or LH
in acute ovarian injury.20 As they become abnormal, the
reduction in OR has already reached to such a critical level
that any intervention to preserve fertility proves
unsuccessful.21 This gap prompted us to investigate AMH,
a relatively new marker that may predict ovarian damage
in time. We found that over a period of a month, CYP
treatment led to a significant fall in the serum AMH,
proportionate with the drastic decline in various follicles.
Our results support the work of Kevenaar et al., who
reported strong correlation between serum and
primordial follicles.22 It is worth mentioning that in group
C serum AMH was significantly higher than group B
(p<0.001), however, it was lower than AMH levels
obtained from controls (p=0.101). To the best of our
knowledge, our study reports the strength of AMH in
reflecting protective effects of a-tocopherol against CYP,
for the first time. We support the role of a-tocopherol in
preserving normal reproductive physiology and likewise
it advocates the role of AMH as an accurate maker of OR
that has the potential to reflect acute injury to the gonads
(Figure-2).
As there was no previous study on association between a-
tocopherol administration and AMH, a-tocopherol was
solely administered to group D and possible effects were
noticed. The histo-morphologic analysis and ELISA
confirmed that there was insignificant difference in the
follicular profile or hormonal levels between controls and
group D. Therefore, it could be inferred that a-tocopherol
does not have a potential role in down-regulating AMH
secretion. Moreover, there was mild variation in the levels
of AMH recorded in mice amongst group A and D, but it
can be explained by the fact that literature reports as
much as ten-fold difference in reserve amongst animals of
the same age group.23 This explains the possibility of
wider variation in serum AMH, truly depicting the ovarian
reserve. 
Our results are in line with a human study conducted by
Yu B. et al. that reported a steady fall in the levels of AMH
in cancer patients, treated with CYP. As the literature
highlights that AMH is solely produced by the granulosa
cells of early growing follicles.24 and is devoid of any
feedback loop from the hypothalamus-pituitary axis, it is
emerging as an accurate indicator, devoid of inter-cyclic
variations.25 Furthermore, AMH is establishing as an
early indicator of decreased OR, making it ideal for
screening patients for timely referral to infertility clinics.
Moreover, various occupational hazards such as metals
(lead and mercury), solvents (toluene and glycol ethers),
chemical exposures to anaesthetic gases and
formaldehyde are assumed to be associated with a
decline in fertility. Therefore, we propose that women
exposed to such occupational hazards might be
routinely evaluated for serum AMH, in order to screen
ovarian insufficiency. 
One limitation of our study included the use of animal
model, as it was not feasible to collect the entire ovary
from human samples to evaluate a comprehensive follicle
profile.
Conclusion
There was substantial evidence that the monitoring of
serum AMH may pave the way to screen high-risk patients
who may progress to premature ovarian failure as a result
of acute ovarian injury. Its monitoring may be employed
for screening female workers against environmental and
occupational hazards in various industries. Therefore,
further studies on humans may ascertain the role of
serum AMH evaluation as a suitable marker of ovarian
insufficiency in numerous conditions.
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